Charles Powell, MD
Pulmonary Disease · New York, NYNPI 1922176072
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $652,694 of the $653,950 with a category attached, or 99.8%. Daiichi Sankyo Inc. accounts for 89.6% of it on its own, with 8 other manufacturers making up the rest. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 120 payments — averaging $5449.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$586K
- Astrazeneca UK Limited$21K
- Biontech SE$14K
- Seagen Inc.$11K
- Eisai Inc.$7K
- AstraZeneca$6K
- plus $8K from 3 others
Across 106 payments — averaging $3674.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$390K
What the payments were for
- Consulting fees$652,694100%
- Travel & lodging$7420%
- Food & beverage$5140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 87 | $586,218 |
| Astrazeneca UK Limited | 9 | $21,100 |
| Biontech SE | 5 | $14,236 |
| Seagen Inc. | 3 | $11,438 |
| Eisai Inc. | 1 | $6,868 |
| AstraZeneca | 9 | $6,204 |
| E.r. Squibb & Sons, L.L.C. | 2 | $2,925 |
| Johnson & Johnson | 1 | $2,525 |
| Pfizer | 3 | $2,438 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$653,950 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,515 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in New York
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
- Kenneth BergerNew York$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.